Distribution and Function of Cannabinoid Receptors 1 and 2 in the Rat, Monkey and Human Bladder

Journal of Urology

Volumn 181, Issue 4, 2009, Pages 1939-1948

  Gratzke, Christian ^a,d   Streng, Tomi ^e   Park, Anthony ^a   Christ, George ^a,b   Stief, Christian G ^d   Hedlund, Petter ^b,c   Andersson, Karl Erik ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LUND UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UNIVERSITY OF MUNICH   (Germany)

^e TURKU UNIVERSITY   (Finland)

Author keywords

anandamide; bladder; cannabinoid; multiple sclerosis; receptors; urination

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CALCITONIN; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST; CARBACHOL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ADULT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC NERVE; CLINICAL ARTICLE; CYSTOMETRY; DETRUSOR MUSCLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; MALE; MONKEY; MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SENSORY NERVE; STAINING; WESTERN BLOTTING;

ANIMALS; HUMANS; MACACA MULATTA; MALE; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; URINARY BLADDER;

EID: 62049084948     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.11.079     Document Type: Article

References (21)

1. Andersson K.E., and Wein A.J. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 56 (2004) 581
2. Freeman R.M., Adekanmi O., Waterfield M.R., Waterfield A.E., Wright D., and Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 17 (2006) 636
3. Kalsi V., and Fowler C.J. Therapy Insight: bladder dysfunction associated with multiple sclerosis. Nat Clin Pract Urol 2 (2005) 492
4. Morrisroe SN, Philips BJ, Coyle C, Gibbons E, Ballesteros I, de Miguel F et al: Cannabinoid receptors in bladder: novel therapeutic targets for interstitial cystitis/painful bladder syndrome. Presented at Society for Urodynamics and Female Urology, San Diego, California, February 21-24, 2007.
5. Martin R.S., Luong L.A., Welsh N.J., Eglen R.M., Martin G.R., and MacLennan S.J. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br J Pharmacol 129 (2000) 1707
6. Pertwee R.G., and Fernando S.R. Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 118 (1996) 2053
7. Farquhar-Smith W.P., Jaggar S.I., and Rice A.S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 97 (2002) 11
8. Jaggar S.I., Hasnie F.S., Sellaturay S., and Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76 (1998) 189
9. Gratzke C., Streng T., Waldkirch E., Sigl K., Stief C., Andersson K.E., et al. Transient receptor potential A1 (TRPA1) activity in the human urethra-evidence for a functional role for TRPA1 in the outflow region. Eur Urol (2008) Epub ahead of print
10. Saitoh C., Kitada C., Uchida W., Chancellor M.B., de Groat W.C., and Yoshimura N. The differential contractile responses to capsaicin and anandamide in muscle strips isolated from the rat urinary bladder. Eur J Pharmacol 570 (2007) 182
11. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452
12. Horvath G., Kekesi G., Nagy E., and Benedek G. The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. Pain 134 (2008) 277
13. Dinis P., Charrua A., Avelino A., Yaqoob M., Bevan S., Nagy I., et al. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 24 (2004) 11253
14. Patwardhan A.M., Jeske N.A., Price T.J., Gamper N., Akopian A.N., and Hargreaves K.M. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A 103 (2006) 11393
15. Jeske N.A., Patwardhan A.M., Gamper N., Price T.J., Akopian A.N., and Hargreaves K.M. Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons. J Biol Chem 281 (2006) 32879
16. Stander S., Schmelz M., Metze D., Luger T., and Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38 (2005) 177
17. Rukwied R., Watkinson A., McGlone F., and Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102 (2003) 283
18. Bridges D., Ahmad K., and Rice A.S. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133 (2001) 586
19. Ellington H.C., Cotter M.A., Cameron N.E., and Ross R.A. The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology 42 (2002) 966
20. Mule F., Amato A., Baldassano S., and Serio R. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Pharmacol Res 56 (2007) 185
21. Brady C.M., DasGupta R., Dalton C., Wiseman O.J., Berkley K.J., and Fowler C.J. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10 (2004) 425